Edition:
United States

Calithera Biosciences Inc (CALA.OQ)

CALA.OQ on NASDAQ Stock Exchange Global Select Market

4.70USD
16 Jul 2018
Change (% chg)

$-0.05 (-1.05%)
Prev Close
$4.75
Open
$4.75
Day's High
$4.75
Day's Low
$4.55
Volume
31,003
Avg. Vol
70,811
52-wk High
$18.85
52-wk Low
$4.30

Select another date:

Thu, May 10 2018

BRIEF-Calithera Biosciences Q1 Loss Per Share $0.37

* CALITHERA BIOSCIENCES REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND RECENT HIGHLIGHTS

BRIEF-Calithera Biosciences Announces FDA Fast Track Designation Granted To CB-839 In Combination With Cabozantinib For Treatment Of Patients With Advanced Renal Cell Carcinoma

* CALITHERA BIOSCIENCES ANNOUNCES FDA FAST TRACK DESIGNATION GRANTED TO CB-839 IN COMBINATION WITH CABOZANTINIB FOR TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA Source text for Eikon: Further company coverage:

BRIEF-Calithera Biosciences Qtrly Net Loss From Operations $11.0 Mln

* CALITHERA BIOSCIENCES REPORTS FOURTH QUARTER 2017 FINANCIAL RESULTS AND RECENT HIGHLIGHTS

BRIEF-Calithera Biosciences Says Plans To Initiate A Global, Randomized Phase 2 Trial Of CB-839 In Combination With Cabozantinib In Q2 Of 2018

* CALITHERA BIOSCIENCES INC - PLAN TO INITIATE A GLOBAL, RANDOMIZED PHASE 2 TRIAL OF CB-839 IN COMBINATION WITH CABOZANTINIB IN Q2 OF 2018 Source text for Eikon: Further company coverage:

Select another date: